Charles River Laboratories International, Inc. (CRL)
| Market Cap | 13.87B |
| Revenue (ttm) | 2.82B |
| Net Income (ttm) | 301.46M |
| Shares Out | 49.70M |
| EPS (ttm) | 6.00 |
| PE Ratio | 46.50 |
| Forward PE | 29.94 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $278.89 |
| Previous Close | $273.72 |
| Change ($) | 5.17 |
| Change (%) | 1.89% |
| Day's Open | 275.72 |
| Day's Range | 274.14 - 280.10 |
| Day's Volume | 376,014 |
| 52-Week Range | 98.90 - 280.10 |
WILMINGTON, Mass. & SHANGHAI--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced that it has entered into a strategic partnership with JADE Biomedical to expand global biologics capa...
Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to present at J.P. Morgan Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River acquires Distributed Bio, a next-generation antibody discovery company, to establish a premier, large molecule discovery...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories to present at upcoming conferences
Charles River reported Q3 2020 results that beat the top- and bottom-line estimates. Moreover, the company has beat analysts' earnings estimates in each of the last eight quarters. Charles Riv...
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
Charles River Laboratories International (CRL) CEO James Foster on Q3 2020 Results - Earnings Call Transcript
Charles River Laboratories International, Inc.'s (CRL) CEO James Foster On Q3 2020 Results - Quick Version Earnings Call Transcript
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Third-Quarter 2020 Results
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-...
Is Charles River Laboratories International Inc. (NYSE:CRL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the ...
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
After the broader markets closed yesterday sharply down, the indices were set to rise today amidst optimism on a stimulus package and strong earnings. For investors looking to make sense of th...
Big economic data this week will be released, including housing market updates, the Conference Board's leading economic index, and the IHS Markit update on some of its indexes. For investors l...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #boardofdirectors--Charles River Laboratories appoints George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals,...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Schedules Third-Quarter 2020 Earnings Release and Conference Call
Sentiment at the end of last week was wrought with uncertainty as President Trump tested positive for COVID-19, amidst the already tense economic and political situation. For investors looking...
The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should cont...
Stocks Hit Resistance; Taiwan Semi, Horizon, Charles River Break Out
Stocks Hit Resistance; Taiwan Semi, Horizon Therapeutics, Charles River break out.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories to present at September investor conferences
The Dow opened 100 points higher backed up by financial stocks and value plays as strong results for Target and Lowe’s gave an indication that retail sales are back on track. Using our deep le...
In Washington, it seems unlikely that the stimulus package would be agreed to in August at this point and could dampen the spirits of investors going forward if nothing is agreed to. Our deep ...
Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2020 Results - Earnings Call Transcript
Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Second-Quarter 2020 Results
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Labs International is in a potential buy area with earnings on tap for Aug. 5. The stock is approximately 2% above a 189.95 buy point from a second-stage.
Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover...
As of late, it has definitely been a great time to be an investor in Charles River Laboratories.
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q1 2020 Results - Earnings Call Transcript
Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Distributed Bio CEO on developing therapeutic antibody treatment against coronavirus
CNBC's "Squawk on the Street" team discusses the possibility of a coronavirus cure with Jake Glanville, CEO of Distributed Bio.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River Laboratories CEO: Biotech companies are 'growing exponentially
CNBC's Jim Cramer chats with Charles River Laboratories CEO Jim Foster to get a read on the drug research and evelopment landscape and the company's plans in China.
Charles River Laboratories International's (CRL) CEO Jim Foster on Q4 2019 Results -Earnings Call Transcript
Charles River (CRL) delivered earnings and revenue surprises of 9.84% and 0.94%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charles River Laboratories: Headwinds Ahead But That's Okay
Charles River Labs CEO: We see high single-digit growth over five years
Jim Cramer checks in with Charles River Labs CEO James Foster to get a read on how the stock could get back on track in the future.
Charles River Laboratories International, Inc. (CRL) CEO Jim Foster on Q3 2019 Results - Earnings Call Transcript
About CRL
Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research a... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 23, 2000 |
| CEO James Foster | Employees 17,100 |
| Stock Exchange NYSE | Ticker Symbol CRL |
Financial Performance
In 2019, CRL's revenue was $2.62 billion, an increase of 15.67% compared to the previous year's $2.27 billion. Earnings were $252.02 million, an increase of 11.33%.
Analyst Forecasts
According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 265.71, which is a decrease of -4.73% from the latest price.